Showing results (91-100 of 190) with videos related to

Sort By:
Pageof 19
Targeted Oncology|September 25, 2015
Effect of Renal Impairment on the Pharmacokinetics and Safety of AxitinibYing Chen, Brian I Rini, Robert J Motzer, et al.
Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)Wenxin Xu, Mäneka Puligandla, Brian Halbert, et al.
Medical Oncology (Northwood, London, England)|January 29, 2010
Detection of a new embryonic antigen (ESA-10) in the blood of patients with cancer: preliminary results in the United StatesPeter H Wiernik, Dahlia Elkadi, Alvaro Luongo-Cespedes, et al.
Journal of Clinical Pharmacology|April 5, 2013
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysisBrian I Rini, May Garrett, Bill Poland, et al.
American Journal of Clinical Oncology|August 7, 2003
Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphomaHuda Salman, Alejandra Perez, Joseph A Sparano, et al.
Pageof 19